- Home
- SEIC vs EXEL Comparison
SEIC vs EXEL Comparison
Compare SEIC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SEIC | EXEL |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | SEIC | EXEL |
|---|---|---|
| Price | $81.06 | $44.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 24 |
| Target Price | ★ $100.29 | $44.73 |
| AVG Volume (30 Days) | 537.1K | ★ 2.5M |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | 30.71 | ★ 53.55 |
| EPS | ★ 5.43 | 2.38 |
| Revenue | $2,246,646,000.00 | ★ $2,288,218,000.00 |
| Revenue This Year | $9.87 | $9.14 |
| Revenue Next Year | $8.01 | $12.51 |
| P/E Ratio | ★ $14.95 | $18.67 |
| Revenue Growth | 9.44 | ★ 9.93 |
| 52 Week Low | $64.66 | $31.90 |
| 52 Week High | $93.96 | $49.62 |
Technical Indicators
Market Signals| Indicator | SEIC | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 63.52 |
| Support Level | $79.69 | $43.00 |
| Resistance Level | $82.18 | $44.79 |
| Average True Range (ATR) | 1.41 | 1.03 |
| MACD | 0.23 | 0.06 |
| Stochastic Oscillator | 76.04 | 83.48 |
Price Performance
Historical ComparisonAbout SEIC SEI Investments Company
SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $87 billion in assets under management. As of December 2024, SEI (including LSV) manages, administers, or advises about $1.6 trillion in assets.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.